Navigation Links
Biotel Announces Profitable Second Quarter Ended December 31, 2008
Date:2/12/2009

MINNEAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) announced results for its second quarter ended December 31, 2008, with net earnings of $289,000, or $0.10 per diluted share, on revenues of $3,186,000. This compares to net earnings of $206,000, or $0.07 per diluted share, on revenues of $2,859,000 for the second quarter of last year. For the six months ended December 31, 2008, Biotel had net earnings of $617,000, or $0.22 per diluted share, on revenues of $6,354,000. This compares to net earnings of $376,000, or $0.13 per diluted share, on revenues of $5,610.000 for the first six months of last year.

    Highlights for the second quarter are as follows:

    * Ninth consecutive profitable quarter
    * Net income up 40.3% year over year
    * Strong gross margin of 45.9%, versus 44.7% a year ago
    * Strong balance sheet with no long-term bank debt
    * Stockholders' equity of $5,320,000, up 22.8% year over year

"We are pleased with Biotel's revenue growth, margin improvement and overall performance in the second quarter," Biotel President and CEO Steve Springrose said. "Sales of the Braemar ER920W wireless arrhythmia monitor remained strong as one of our OEM partners continued ordering product for inventory stocking. We expect sales to this customer to diminish in the second half. Sales of Braemar Holter devices, event recorders, liposuction equipment and other medical devices remained solid. Having received FDA 510(k) approval of our Fusion platform of wireless ECG monitoring products, we are beginning shipments of an evaluation version of the product this quarter, followed by a planned limited clinical release and distribution of Fusion products in our fourth quarter. Biotel serves as a development partner to medical corporations seeking new devices and clinical research services."



                               3 months ended  3 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $3,186,000      $2,859,000         11.4%
    Net Income                     $289,000        $206,000         40.3%
    Earnings Per Share, Basic         $0.10           $0.08
    Earnings Per Share, Diluted       $0.10           $0.07



                               6 months ended  6 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $6,354,000      $5,610,000         13.3%
    Net Income                     $617,000        $376,000         64.2%
    Earnings Per Share, Basic         $0.22           $0.14
    Earnings Per Share, Diluted       $0.22           $0.13

'/>"/>
SOURCE Biotel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biotel Announces Profitable Third Quarter Ended March 31, 2008
2. Biotel Announces Strong Results for the Second Quarter Ended December 31, 2007
3. Biotel Announces Strong Results for the First Quarter Ended September 30, 2007, FDA 510(k) Clearance for the Braemar ER900 Wireless Event Recorder
4. Biotel Announces Record Revenues and Strong Earnings for the Fourth Quarter and Year Ended June 30, 2007
5. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
6. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
7. Cogdell Spencer Announces Dorr as President of the Southeast Region
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
9. Terri Lynne Lokoff Child Care Foundation Announces Recipients of the 2009 Terri Lynne Lokoff/Childrens TYLENOL(R) National Child Care Teacher Awards(TM)
10. Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices
11. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Lake Park Dental ... by using Invisalign® in Lutz, FL. With the help of this highly-effective, ... aesthetics with fewer potential complications, more discretion and less pain. , Drs. Sarah ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Buyers and ... recreational users to dispensaries and head shops –can’t help but be heartened by the ... the tell-tale cannabis odor aptly described as “skunk smell.” At last they can ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection ... Pink is proud to announce Katie Thiede as their new Chief Executive Officer. In January, ... Chairman of the Board and launched a national search to find a visionary new leader ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology: